FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVA

OMB Number: 3235-0287 Estimated average burden 0.5 hours per response:

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.	
1. Name and Address of Reporting Person* Zanganeh Mahkam	2. Issuer Name and Ticker or Trading Symbol Summit Therapeutics Inc. [SM

1. Name and Address of Reporting Person* Zanganeh Mahkam		Person*	2. Issuer Name and Ticker or Trading Symbol Summit Therapeutics Inc. [SMMT]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
Zanganen	<u>Mankam</u>		[Similir]	X	Director	X	10% Owner		
(Last)	(First)	(Middle)	_	X	Officer (give title below)		Other (specify below)		
` ′	T THERAPEUT	,	3. Date of Earliest Transaction (Month/Day/Year) 05/30/2025		Co-Chief				
601 BRICKE	ELL KEY DRIVE	E, SUITE 1000			Executive Officer				
-			_		Officer				
(Street)	. Total	22121	4. If Amendment, Date of Original Filed (Month/Day/Year)		vidual or Joint/Group	Filing (Check Applicable		
MIAMI	FL	33131		Line)	Form filed by One	Renor	ing Person		
	,	<i>_</i>			Form filed by Mor		•		
(City)	(State)	(Zip)			Person	e tilali v	one reporting		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	05/30/2025		M ⁽¹⁾		74,545	A	\$2.64	555,754,696(2)	I	By Spouse
Common Stock								10,199,776 ⁽²⁾	I	By the Shaun Zanganeh Irrevocable Trust, with the Reporting Person as Trustee
Common Stock								25,457,666 ⁽²⁾	I	By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee
Common Stock								50,000(2)	I	Immediate family member
Common Stock								31,000	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 11. Nature 1. Title of Derivative Security (Instr. 3) 3A. Deemed Execution Date, if any (Month/Day/Year) 8. Price of Derivative Security (Instr. 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 9. Number of 3. Transaction 5. Number 7. Title and Amount of Securities 9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4) Conversion Transaction Ownership of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) or Exercise Price of Derivative Security Underlying Derivative Security (Instr. 3 and 4) Ownership Form: Direct (D) or Indirect (I) (Instr. 4) Beneficial Ownership (Instr. 4) Code (Instr. 8) (Month/Day/Year) ction(s) (Instr. 4) Amount or Number Date Expiration Code (A) (D) Exercisable Date Title Shares Stock Option (right to 05/30/2025 $M^{(1)}$ (3) **0**⁽²⁾ 01/02/2034 74,545 By Spouse Stock

Explanation of Responses:

- 1. On May 30, 2025, the Reporting Person's spouse exercised an option to purchase 74,545 shares of the Issuer's common stock at an exercise price of \$2.64 per share. The Reporting Person's spouse did not sell
- 2. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
- 3. The option was granted on January 2, 2024. The shares underlying the option vested in four equal quarterly installments on March 31, June 30, September 30 and December 31, 2024.

Remarks:

/s/ Mahkam Zanganeh

06/02/2025

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.